.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,359,016

« Back to Dashboard

Claims for Patent: 6,359,016

Title: Topical suspension formulations containing ciprofloxacin and dexamethasone
Abstract:Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.
Inventor(s): Singh; Onkar N. (Arlington, TX), Bhagat; Haresh G. (Fort Worth, TX)
Assignee: Alcon Universal Ltd. (Hunenberg, CH)
Application Number:09/865,783
Patent Claims: 1. A topically administrable aqueous suspension composition intended for application to the eye, ear or nose consisting essentially of

a) 0.01-0.5% (wt.) dexamethasone;

b) 0.1-0.4% (wt.) ciprofloxacin;

c) NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm, provided that such amount is greater than 0.3% (wt.);

d) 0.1-0.5% (wt.) of a nonionic polymer;

e) 0.01-0.2% (wt.) of a nonionic surfactant; and

f) a buffer,

wherein the composition has a pH of 4.5.+-.0.2, the dexamethasone is selected from the group consisting of dexamethasone alcohol and dexamethasone acetate; and the ciprofloxacin is ciprofloxacin hydrochloride, monohydrate, and further wherein the composition optionally comprises a preservative, optionally comprises boric acid, optionally comprises a pH-adjusting agent and optionally comprises a chelating agent.

2. A topically administrable aqueous suspension composition intended for application to the eye, ear or nose consisting essentially of

a) 0.01-0.5% (wt.) dexamethasone;

b) 0.1-0.4% (wt.) ciprofloxacin;

c) NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm, provided that such amount is greater than 0.3% (wt.);

d) 0.1-0.5% (wt.) of a nonionic polymer;

e) 0.01-0.2% (wt.) of a nonionic surfactant; and

f) a buffer,

wherein the composition has a pH of 4.5.+-.0.2, the nonionic polymer is hydroxyethyl cellulose, the hydroxyethyl cellulose is present in a concentration of 0.2% (wt.), the nonionic surfactant is tyloxapol, and the tyloxapol is present in a concentration of 0.05% (wt.), and further wherein the composition optionally comprises a preservative, optionally comprises boric acid, optionally comprises a pH-adjusting agent and optionally comprises a chelating agent.

3. A topically administrable aqueous suspension composition intended for application of the eye, ear or nose consisting essentially of

a) 0.01-0.5% (wt.) dexamethasone;

b) 0.1-0.4% (wt.) ciprofloxacin;

c) NaCl in an amount sufficient to cause the composition to have an osmolality of about 250-350 mOsm, provided that such amount is greater than 0.3% (wt.);

d) 0.1-0.5% (wt.) of a nonionic polymer;

e) 0.01-0.2% (wt.) of a nonionic surfactant; and

f) a buffer,

wherein the composition has a pH of 4.5.+-.0.2 and the composition further comprises 0.005-0.3% (wt.) of a quaternary ammonium halide, 0.001-0.1% (wt.) of a chelating agent; and 0.1-1.5% (wt.) of boric acid, and optionally comprises a pH-adjusting agent.

4. The composition of claim 3 wherein the quaternary ammonium halide is selected from the group consisting of polyquaternium-1 and benzalkonium halides; and the chelating agent is selected from the group consisting of edetate disodium; edetate trisodium; edetate tetrasodium; and diethyleneamine pentaacetate.

5. The composition of claim 4 wherein the quaternary ammonium halide is benzalkonium chloride and the chelating agent is edetate disodium.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc